Abstract | BACKGROUND: METHOD: Under a double-blind procedure, 122 patients suffering from general anxiety disorders were randomly allocated to either alpidem (50 mg, three times a day) or alprazolam (0.5 mg, three times a day) for six weeks, followed by a two-week placebo withdrawal phase. The diagnosis of withdrawal syndrome (WS) was made, in blind conditions, on the basis of the Withdrawal Symptom Check List (WSCL), after one or two weeks of discontinuation of active treatment. RESULTS: The WS occurred significantly less frequently in the alpidem group (n = 10, 18%) than in the alprazolam group (n = 26, 48%). Typical withdrawal symptoms on the WSCL were also significantly less severe (P = 0.044) in the alpidem group compared with the alprazolam group. CONCLUSIONS:
|
Authors | L Frattola, M Garreau, R Piolti, S Bassi, M G Albizzati, C Borghi, P L Morselli |
Journal | The British journal of psychiatry : the journal of mental science
(Br J Psychiatry)
Vol. 165
Issue 1
Pg. 94-100
(Jul 1994)
ISSN: 0007-1250 [Print] England |
PMID | 7802852
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Anxiety Agents
- Imidazoles
- Pyridines
- alpidem
- Alprazolam
|
Topics |
- Adult
- Alprazolam
(administration & dosage, adverse effects)
- Anti-Anxiety Agents
(administration & dosage, adverse effects)
- Anxiety Disorders
(drug therapy, psychology)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Imidazoles
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Neurologic Examination
(drug effects)
- Personality Assessment
- Pyridines
(administration & dosage, adverse effects)
- Substance Withdrawal Syndrome
(etiology)
- Treatment Outcome
|